Interleukin-6 as a Risk and Prognostic Biomarker in Gastric Cancer: A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.30683/1929-2279.2024.13.07Keywords:
Interleukin-6, Stomach Neoplasms, systematic review, meta-analysis (Source: MeSH)Abstract
Introduction: Gastric cancer (GC) is one of the leading causes of cancer-related mortality worldwide. Interleukin-6 (IL-6) has been implicated in its pathogenesis and progression, but its role as a prognostic biomarker remains controversial.
Objective: To evaluate the association between serum IL-6 levels and the risk or prognosis in patients with GC through a systematic review (SR) and meta-analysis.
Methods: A SR was conducted in PubMed, Scopus, EMBASE, and Web of Science. Inclusion criteria were studies in adults that assessed the risk or prognostic capacity of IL-6 in GC, with quantifiable association measures such as hazard ratio (HR) or relative risk (RR). Studies focusing on specific populations or lacking survival data were excluded. Methodological quality was assessed using the Newcastle-Ottawa Scale. A meta-analysis using a DerSimonian and Laird random-effects model was performed.
Results: Four studies (two case-control and two retrospective cohort studies) involving a total of 1,007 patients were included. The meta-analysis of cohort studies showed a significant association between elevated IL-6 levels and poorer prognosis (combined HR = 1.71, 95% CI: 1.21-2.43, p = 0.002). Heterogeneity was low (I² = 0%).
Discussion: The results suggest that elevated serum IL-6 is associated with a worse prognosis in GC. However, variability in IL-6 cut-off points and methodological differences between studies limit the generalizability of these findings. Larger, prospective, and standardized studies are needed to validate IL-6's role as a prognostic biomarker in GC and to establish clinically relevant cut-off points.
References
Petryszyn P, Chapelle N, Matysiak-Budnik T. Gastric Cancer: Where Are We Heading? Dig Dis Basel Switz 2020; 38(4): 280-5. https://doi.org/10.1080/17474124.2021.1845140
Yang K, Lu L, Liu H, Wang X, Gao Y, Yang L, et al. A comprehensive update on early gastric cancer: defining terms, etiology, and alarming risk factors. Expert Rev Gastroenterol Hepatol 2021; 15(3): 255-73. https://doi.org/10.1080/17474124.2021.1845140
Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci 2020; 21(11): 4012. https://doi.org/10.3390/ijms21114012
López MJ, Carbajal J, Alfaro AL, Saravia LG, Zanabria D, Araujo JM, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol 2023; 181: 103841. https://doi.org/10.1016/j.critrevonc.2022.103841
Norwood DA, Montalvan-Sanchez E, Dominguez RL, Morgan DR. Gastric Cancer: Emerging Trends in Prevention, Diagnosis, and Treatment. Gastroenterol Clin North Am 2022; 51(3): 501-18. https://doi.org/10.1016/j.gtc.2022.05.001
Roșu MC, Ardelean A, Moldovan SD, Faur FI, Nesiu A, Totoloci BD. The importance of CA 72-4 and CA 19-9 dosing in gastric cancer. J Med Life 2023; 16(2): 186-8. https://doi.org/10.25122/jml-2022-0173
Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med 2020; 217(5): e20190347. https://doi.org/10.1084/jem.20190347
Attar M, Mansoori M, Shahbazi M. Interleukin-6 Genetic Variation and Susceptibility to Gastric Cancer in an Iranian Population. Asian Pac J Cancer Prev APJCP 2017; 18(11): 3025-9. https://doi.org/10.22034/APJCP.2017.18.11.3025
Santos MP, Pereira JN, Delabio RW, Smith MAC, Payão SLM, Carneiro LC, et al. Increased expression of interleukin-6 gene in gastritis and gastric cancer. Braz J Med Biol Res 2021; 54(7): e10687. https://doi.org/10.1590/1414-431X2020e10687
Xu M, Ren L, Fan J, Huang L, Zhou L, Li X, et al. Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6. Life Sci 2022; 290: 120266. https://doi.org/10.1016/j.lfs.2021.120266
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; n71. https://doi.org/10.1136/bmj.n71
Ottawa Hospital Research Institute [Internet]. [citado el 27 de mayo de 2024]. Disponible en:
https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Nobakht H, Saghafi M, Ghorbani R, Mansori K, Fatemi SR, Allahmoradi M, et al. Evaluation of the Serum Levels of TNF-α and Interleukin-6 as Potential Diagnostic Biomarkers in the First-Degree Relatives of Patients with Gastric Cancer: A Case-Control Study. Middle East J Cancer [Internet] 2023 [citado el 15 de agosto de 2024];14(3). https://doi.org/10.30476/mejc.2022.94412.1724
Wong H-L, Rabkin CS, Shu X-O, Pfeiffer RM, Cai Q, Ji B-T, et al. Systemic cytokine levels and subsequent risk of gastric cancer in Chinese Women. Cancer Sci 2011; 102(10): 1911-5. https://doi.org/10.1111/j.1349-7006.2011.02033.x
Liang P, Zhang Y, Jiang T, Jin T, Chen Z, Li Z, et al. Association between IL-6 and prognosis of gastric cancer: a retrospective study. Ther Adv Gastroenterol 2023; 16: https://doi.org/10.1177/17562848231211543
Liao W-C, Lin J-T, Wu C-Y, Huang S-P, Lin M-T, Wu AS-H, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 2008; 14(2): 428-34. https://doi.org/10.1158/1078-0432.CCR-07-1032
Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, et al. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc 2005; 8(2): 124-31. https://doi.org/10.1007/s10120-005-0315-x
Kim D-K, Oh SY, Kwon H-C, Lee S, Kwon KA, Kim BG, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009; 9(1): 155. https://doi.org/10.1186/1471-2407-9-155
Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y. Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol WJG 2006; 12(28): 4473-7. https://doi.org/10.3748/wjg.v12.i28. 4473
Szor DJ, Dias AR, Pereira MA, Ramos MFKP, Zilberstein B, Cecconello I, et al. Prognostic Role of Neutrophil/Lymphocyte Ratio in Resected Gastric Cancer: A Systematic Review and Meta-analysis. Clin Sao Paulo Braz 2018; 73: e360. https://doi.org/10.6061/clinics/2018/e360
Hara M, Nagasaki T, Shiga K, Takahashi H, Takeyama H. High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab. Surg Today 2017; 47(4): 483-9. https://doi.org/10.1007/s00595-016-1404-7
Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, et al. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol Off J Am Soc Clin Oncol 2003; 21(12): 2282-7. https://doi.org/10.1200/JCO.2003.06.103
Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget 2018; 9(51): 29820-41. https://doi.org/10.18632/oncotarget. 25661
Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 2018; 15(4): 234-48. https://doi.org/10.1038/nrclinonc.2018.8
Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res 2014; 74(1): 8-14. https://doi.org/10.1158/0008-5472.CAN-13-2322
Du W, Tang H, Lei Z, Zhu J, Zeng Y, Liu Z, et al. miR-335-5p inhibits TGF-β1-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1. Respir Res 2019; 20(1): 225. https://doi.org/10.1186/s12931-019-1184-x
Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H, et al. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci 2017; 108(10): 1947-52. https://doi.org/10.1111/cas.13332
Zhao G, Zhu G, Huang Y, Zheng W, Hua J, Yang S, et al. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer. Oncol Rep 2016; 35(3): 1787-95. https://doi.org/10.3892/or.2016.4544
Kinoshita H, Hirata Y, Nakagawa H, Sakamoto K, Hayakawa Y, Takahashi R, et al. Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis. PloS One 2013; 8(4): e60914. https://doi.org/10.1371/journal.pone. 0060914
Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget 2017; 8(13): 20741-50. https://doi.org/10.18632/oncotarget.15119
Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38(7): 904-10. https://doi.org/10.1016/j.ctrv.2012.04.007
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.